Johannes Gerardus Chri Schikan Sells 30,712 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the transaction, the director owned 315,167 shares in the company, valued at approximately $11,185,276.83. The trade was a 8.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total transaction of $241,424.40.
• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40.
• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The stock was sold at an average price of $30.07, for a total transaction of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total value of $210,350.00.

Pharvaris Stock Performance

NASDAQ PHVS traded down $0.63 on Wednesday, reaching $33.95. 376,128 shares of the stock traded hands, compared to its average volume of 409,202. Pharvaris N.V. has a 12 month low of $17.05 and a 12 month high of $35.90. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -10.68 and a beta of -2.34. The company has a fifty day moving average price of $30.90 and a 200-day moving average price of $28.21.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, research analysts anticipate that Pharvaris N.V. will post -3.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Seven Fleet Capital Management LP boosted its stake in Pharvaris by 472.3% in the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after acquiring an additional 261,355 shares in the last quarter. DV Trading LLC purchased a new stake in shares of Pharvaris in the 1st quarter valued at $4,067,000. Stempoint Capital LP increased its stake in shares of Pharvaris by 48.4% in the first quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock worth $2,447,000 after acquiring an additional 28,248 shares during the period. ADAR1 Capital Management LLC raised its holdings in shares of Pharvaris by 23.4% during the first quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock worth $2,981,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Amundi lifted its position in Pharvaris by 12.0% during the first quarter. Amundi now owns 30,952 shares of the company’s stock valued at $874,000 after purchasing an additional 3,312 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PHVS shares. Wedbush boosted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Wall Street Zen raised shares of Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Citizens Jmp reduced their price objective on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $49.64.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.